LBMI at FORTH-IESL’s Post

#Bioluminescence and #Fluorescence Imaging with φ-eye™ 🔬 In this study conducted in collaboration with the LBMI at FORTH-IESL team and led by Giannis Zacharakis, a mouse 🐭 bearing a subcutaneous U87MG_Luc2 tumor was monitored over time. The combination of bioluminescence (BLI) and fluorescence (FLI) provided complementary insights into tumor progression and tracer distribution. 🌟 Bioluminescence Imaging (#BLI): By administering D-luciferin (IVISbrite RediJect), the luciferase-expressing tumor cells produced light that could be detected 𝑖𝑛 𝑣𝑖𝑣𝑜. Over the course of the study, the signal remained relatively stable during the early days and showed a sharp increase after day 49, reflecting the active proliferation of tumor cells. 🧪 Fluorescence Imaging (#FLI): A near-infrared (NIR) fluorescent tracer was also used to visualize biodistribution. The images revealed tracer accumulation in the tumor region, but also in clearance organs such as the liver and intestines, which is typical for such probes. 📈 Kinetic and Growth Analysis: The luciferin kinetic curve shows the expected pattern: a peak intensity around 18–20 minutes post injection, followed by a gradual decline. Tumor growth analysis confirmed a delayed expansion phase, followed by rapid increase in tumor area after approximately 7 weeks. 📢 Conclusion: The results demonstrate how φ-eye™ enables non-invasive, longitudinal monitoring of tumor growth and tracer biodistribution in small animals. By combining BLI and FLI, researchers can gain valuable insights into both cellular activity and drug behavior over time. 👉 Click the link to explore the system capabilities: https://lnkd.in/dpMj_xKU #TumorGrowth #TracerBiodistribution #Oncology